After intravenous injection of AGAP, central nervous system diseases such as epilepsy and migraine were not observed in mice, so the combinations of AGAP with the VGSC subtypes mainly distributed in this region (Nav1.1, Nav1.2, Nav1.3, and Nav1.6) were not examined in this study. This evidence concerns the gene SCN2A and migraine disorder.